Literature DB >> 2597989

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.

B G Weinshenker1, B Bass, G P Rice, J Noseworthy, W Carriere, J Baskerville, G C Ebers.   

Abstract

Controversy exists regarding the predictive value of the early clinical course of multiple sclerosis (MS). Three parameters often considered are the attack rate, the first interattack interval and the rate at which disability develops in the early years of the disease. We have recorded the time to reach successive levels of disability defined by the Kurtzke Disability Status Scale (DSS) in 1,099 MS patients followed at University Hospital, London, Canada between 1972 and 1984. Our population is particularly suitable because of its size, the high degree of ascertainment of cases in the community, and the regular follow-up provided. Life table analysis was used to compare survival in patients stratified according to the above three parameters using DSS 6 as end point. Significant differences were evident in the survival distributions. Despite the extensive interindividual variation in the rate at which disability developed, the early course of MS may be useful in determining the relative risk of rapid progression.

Entities:  

Mesh:

Year:  1989        PMID: 2597989     DOI: 10.1093/brain/112.6.1419

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  114 in total

1.  Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life.

Authors:  D Parkin; A Jacoby; P McNamee; P Miller; S Thomas; D Bates
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-02       Impact factor: 10.154

2.  Natural history of multiple sclerosis.

Authors:  G C Ebers
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

Review 3.  Interferon in relapsing-remitting multiple sclerosis.

Authors:  G P Rice; B Incorvaia; L Munari; G Ebers; C Polman; R D'Amico; G Filippini
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 4.  Benign multiple sclerosis: does it exist?

Authors:  Jorge Correale; María C Ysrraelit; Marcela P Fiol
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

5.  Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.

Authors:  R B Forbes; A Lees; N Waugh; R J Swingler
Journal:  BMJ       Date:  1999-12-11

6.  Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

Authors:  Valentina Tomassini; Andrea Paolillo; Pierluigi Russo; Elisabetta Giugni; Luca Prosperini; Claudio Gasperini; Guido Antonelli; Stefano Bastianello; Carlo Pozzilli
Journal:  J Neurol       Date:  2005-09-14       Impact factor: 4.849

7.  Prognostic criteria in an epidemiological group of patients with multiple sclerosis: an exploratory study.

Authors:  K Lauer; W Firnhaber
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

8.  Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications.

Authors:  Shien Guo; Duygu Bozkaya; Alexandra Ward; Judith A O'Brien; Khajak Ishak; Randy Bennett; Ahmad Al-Sabbagh; Dennis M Meletiche
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  Quantitative risk-benefit analysis of natalizumab.

Authors:  J P Thompson; K Noyes; E R Dorsey; S R Schwid; R G Holloway
Journal:  Neurology       Date:  2008-07-29       Impact factor: 9.910

10.  Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

Authors:  Ray Gani; Gavin Giovannoni; David Bates; Belinda Kemball; Steve Hughes; John Kerrigan
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.